255 related articles for article (PubMed ID: 32511022)
41. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
[TBL] [Abstract][Full Text] [Related]
42. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
Richard S; Jagannath S
BioDrugs; 2022 Jan; 36(1):13-25. PubMed ID: 35113384
[TBL] [Abstract][Full Text] [Related]
43. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
44. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
[TBL] [Abstract][Full Text] [Related]
45. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
Gerecitano J
J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264
[TBL] [Abstract][Full Text] [Related]
46. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
Garg M; Kanojia D; Mayakonda A; Said JW; Doan NB; Chien W; Ganesan TS; Chuang LS; Venkatachalam N; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Oncotarget; 2017 Jan; 8(5):7521-7532. PubMed ID: 27893412
[TBL] [Abstract][Full Text] [Related]
47. Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.
Remaggi G; Ochoa PA; Garate GM
Am J Case Rep; 2022 Jul; 23():e936505. PubMed ID: 35834427
[TBL] [Abstract][Full Text] [Related]
48. Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma.
Hu F; Chen XQ; Li XP; Lu YX; Chen SL; Wang DW; Liang Y; Dai YJ
Int Immunopharmacol; 2022 Jul; 108():108722. PubMed ID: 35381563
[TBL] [Abstract][Full Text] [Related]
49. Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
Malandrakis P; Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
Onco Targets Ther; 2020; 13():6405-6416. PubMed ID: 32669858
[TBL] [Abstract][Full Text] [Related]
50. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
51. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
[TBL] [Abstract][Full Text] [Related]
52. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract][Full Text] [Related]
53. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract][Full Text] [Related]
55. Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Salcedo M; Lendvai N; Mastey D; Schlossman J; Hultcrantz M; Korde N; Mailankody S; Lesokhin A; Hassoun H; Smith E; Shah U; Diab V; Werner K; Landau H; Lahoud O; Drullinsky P; Shah G; Chung D; Scordo M; Giralt S; Landgren O
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):198-200. PubMed ID: 32001193
[No Abstract] [Full Text] [Related]
56. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
[TBL] [Abstract][Full Text] [Related]
57. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.
Chari A; Vogl DT; Jagannath S; Jasielec J; Unger TJ; DeCastro A; Shah J; Kauffman M; Shacham S; Jakubowiak A
Br J Haematol; 2020 May; 189(4):e126-e130. PubMed ID: 32124443
[No Abstract] [Full Text] [Related]
58. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
[TBL] [Abstract][Full Text] [Related]
59. Treatment of multiple myeloma with selinexor: a review.
Huang Q; Zhao R; Xu L; Hao X; Tao S
Ther Adv Hematol; 2024; 15():20406207231219442. PubMed ID: 38186637
[TBL] [Abstract][Full Text] [Related]
60. Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.
Chakraborty R; Efficace F
Br J Haematol; 2020 May; 189(3):e112-e113. PubMed ID: 32080829
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
